Abstract

measures (MMSE) in corresponding to underlying AD pathology. The use of a brief test such as the AD8 may improve strategies for detecting dementia in community settings and in developing countries where biomarkers may not be readily available and may also enrich clinical trial recruitment by increasing the likelihood that participants have underlying biomarker abnormalities that are increasingly becoming required for inclusion.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call